Increasing Rates of Maternal Mortality: How Do Overdose Deaths Contribute?
Between 2018 and 2021, pregnancy-associated overdose mortality rates increased among all women in all age groups, tripling in women between the ages of 35 and 44.
Between 2018 and 2021, pregnancy-associated overdose mortality rates increased among all women in all age groups, tripling in women between the ages of 35 and 44.
In this large cohort study analyzing data from publicly insured Medicaid beneficiaries, the overall risk of malformations was lower with buprenorphine than with methadone.
More infants who were exposed to strong agonists and opioids with long half-lives, including methadone, developed neonatal opioid withdrawal syndrome.
Treatment with buprenorphine versus methadone during pregnancy is associated with lower risk of preterm birth, low birth weight, small size for gestational age, and NAS.
Opioid use during pregnancy co-occurs with other variables that are associated with worse outcomes in children, specifically maternal depression and the use of alcohol, tobacco, and other drugs.
More infants who were exposed to strong agonists and opioids with long half-lives, including methadone, developed neonatal opioid withdrawal syndrome.
Several recent studies have examined patterns of opioid use in women receiving opioid prescriptions for pain management after delivery.
Parenting support, maternal bonding with the infant, engagement in an OUD treatment program, and recovery-specific support systems promoted recovery in postpartum women with opioid use disorders.
This study demonstrates higher rates of treatment continuation in postpartum women with opioid use disorders if medication treatment (methadone or buprenorphine) is initiated early and maintained throughout pregnancy.
Previous studies have suggested a link between opioid exposure during pregnancy and increased risk of certain major malformations, including neural tube defects. A recent study from Bateman and colleagues assesses the risk of major malformation [...]